Cysteinyl Leukotriene Blockade Does Not Prevent Acute Mountain Sickness

Aviation Space and Environmental Medicine

Volumn 75, Issue 5, 2004, Pages 413-419

  Muza, Stephen R ^a   Kaminsky, David ^b   Fulco, Charles S ^a   Banderet, Louis E ^a   Cymerman, Allen ^a  

^a U S ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

High altitude illness; Hypoxia; Leukotrienes; Montelukast

Indexed keywords

LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; PLACEBO;

ADULT; ALTITUDE ACCLIMATIZATION; ALTITUDE DISEASE; ANOREXIA; ARTICLE; BLOOD SAMPLING; BRAIN EDEMA; BRAIN HYPOXIA; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEADACHE; HUMAN; INSOMNIA; LASSITUDE; MALAISE; MALE; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM;

ACETATES; ADMINISTRATION, ORAL; ADULT; ALTITUDE SICKNESS; ANALYSIS OF VARIANCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYSTEINE; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MALE; PREVALENCE; QUINOLINES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 2142707262     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bartsch P, Eichenberger U, Ballmer PE, et al. Urinary leukotriene E(4) levels are not increased prior to high-altitude pulmonary edema. Chest 2000; 117:1393-8.
2. Busse WW. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998; 157:S210-3.
3. Campbell WB. Lipid-derived autacoids: Eicosanoids, and platelet-activating factor. In: Gilman AG, Rall TW, Nies AS, et al., eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press; 1990:600-17.
4. Celli B, Criner GJ, Rassulo J. Ventilatory muscle recruitment during unsupported arm exercise in normal subjects. J Appl Physiol 1988; 64:1936-41.
5. Ford-Hutchinson AW. Leukotrienes: Their formation and role as inflammatory mediators. Fed Proc 1985; 44:25-9.
6. Fox E, Shotton K, Ulrich C. SIGMASTAT statistical software user's manual. San Rafael, CA: Jandel Corporation; 1995.
7. Fulco CS, Rock PB, Trad LA, et al. Increased activity augments the incidence and severity of acute mountain sickness (AMS) during a simulated ascent to 4600 M. The FASEB Journal 8, A. 1994.
8. Gardner RM, Hankinson JL, Clausen JL, et al. Standardization of spirometry-1987 update. Am Rev Respir Dis 1987; 136:1285-98.
9. Grover RF, Johnson RL Jr, McCullough RG, et al. Pulmonary hypertension and pulmonary vascular reactivity in beagles at high altitude. J Appl Physiol 1988; 65:2632-40.
10. Hackett PH, Roach RC. High-altitude medicine. In: Auerbach PS, ed. Wilderness medicine. Philadelphia: Mosby; 2001:2-43.
11. Hansen JE, Evans WO. A hypothesis regarding the pathophysiology of acute mountain sickness. Arch Environ Health 1970; 21:666-9.
12. Jarvis B, Markham A. Montelukast: A review of its therapeutic potential in persistent asthma. Drugs 2000; 59:891-928.
13. Johnson TS, Rock PB. Current concepts: Acute mountain sickness. N Engl J Med 1988; 319:841-5.
14. Kaminsky DA, Jones K, Schoene RB, et al. Urinary leukotriene E4 levels in high-altitude pulmonary edema. A possible role for inflammation. Chest 1996; 110:939-45.
15. Krasney JA. A neurogenic basis for acute altitude illness. Med Sci Sports Exerc 1994; 26:195-208.
16. Levine BD, Ellsworth AJ, Rabold M, et al. Viewpoints: By what physiological mechanism is dexamethasone beneficial in the prevention of acute mountain sickness? J Wilderness Med 1993; 4:106-9.
17. Levine BD, Yoshimura K, Kobayashi T, et al. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989; 321:1707-13.
18. Malconian MK, Rock PB. Medical problems related to altitude. In: Pandolf KB, Sawka MN, Gonzalez RR, eds. Human performance physiology and environmental medicine at terrestrial extremes. Indianapolis: Benchmark Press, Inc.; 1988:545-64.
19. Malik AB. Prostaglandins, leukotrienes, and lung fluid balance. Fed Proc 1985; 44:18-9.
20. Meehan RT, Cymerman A, Rock P, et al. The effect of naproxen on acute mountain sickness and vascular responses to hypoxia. Am J Med Sci 1986; 292:15-20.
21. Packer M. Therapeutic application of calcium-channel antagonists for pulmonary hypertension. Am J Cardiol 1985; 55:196B-201B.
22. Richalet JP, Homych A, Rathat C, et al. Plasma prostaglandins, leukotrienes and thromboxane in acute high altitude hypoxia. Respir Physiol 1991; 85:205-15.
23. Roach JM, Muza SR, Rock PB, et al. Urinary leukotriene E4 levels increase upon exposure to hypobaric hypoxia. Chest 1996; 110:946-51.
24. Roach RC, Bartsch P, Oelz O, et al. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Houston CS, Coates G, eds. Hypoxia and molecular biology: Proceedings of the eighth international hypoxia symposium; 9-13 February 1993; Lake Louise, Canada. Burlington, VT: Queen City Press; 1993: 272-4.
25. Sampson JB, Cymerman A, Burse RL, et al. Procedures for the measurement of acute mountain sickness. Aviat Space Environ Med 1983; 54:1063-73.
26. Savourey G, Guinet A, Besnard Y, et al. Evaluation of the Lake Louise acute mountain sickness scoring system in a hypobaric chamber. Aviat Space Environ Med 1995; 66:963-7.
27. Schoene RB, Hackett PH, Henderson WR, et al. High-altitude pulmonary edema: Characteristics of lung lavage fluid. JAMA 1986; 256:63-9.
28. Schoene RB, Swenson ER, Pizzo CJ, et al. The lung at high altitude: Bronchoalveolar lavage in acute mountain sickness and pulmonary edema. J Appl Physiol 1988; 64:2605-13.
29. Singh I, Khanna PK, Srivastava MC, et al. Acute mountain sickness. N Engl J Med 1969; 280:175-84.
30. Sutton JR, Lassen N. Pathophysiology of acute mountain sickness and high altitude pulmonary edema: An hypothesis. Bull Eur Physiolpathol Respir 1979; 15:1045-52.
31. Yao XL, Cowan MJ, Gladwin MT, et al. Dexamethasone alters arachidonate release from human epithelial cells by induction of pll protein synthesis and inhibition of phospholipase A2 activity. J Biol Chem 1999; 274:17202-8.
32. Yoneda K, Talebian M, Wood S, et al. Elevated urinary leukotriene E4 levels at high altitude. High Alt Med Biol 2001; 2:112.